Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astrana Health Inc. - Common Stock (NQ:ASTH)

25.28 +0.63 (+2.56%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrana Health Inc. - Common Stock

< Previous 1 2 Next >
2 Healthcare Stocks with Competitive Advantages and 1 to Keep Off Your Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
1 Russell 2000 Stock on Our Watchlist and 2 to Keep Off Your Radar
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
Healthcare Technology for Providers Stocks Q1 Teardown: Astrana Health (NASDAQ:ASTH) Vs The Rest
Looking back on healthcare technology for providers stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Astrana Health (NASDAQ:ASTH) and its peers. 
Via StockStory
Earnings Scheduled For May 8, 2025
Via Benzinga
What 4 Analyst Ratings Have To Say About Astrana Health
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Healthcare Technology Stocks Q1 Recap: Benchmarking GoodRx (NASDAQ:GDRX)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at healthcare technology stocks, starting... 
Via StockStory
Reflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Tandem Diabetes (NASDAQ:TNDM) and its peers. 
Via StockStory
Astrana Health (ASTH): Buy, Sell, or Hold Post Q1 Earnings?
Astrana Health has gotten torched over the last six months - since November 2024, its stock price has dropped 39.1% to $25.63 per share. This was partly driven by its softer quarterly results and might... 
Via StockStory
Topics Government
Envista, NeoGenomics, Acadia Healthcare, Astrana Health, and Hims & Hers Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could... 
Via StockStory
Topics Bonds Stocks
Astrana Health (NASDAQ:ASTH) Misses Q1 Revenue Estimates
Healthcare services company Astrana Health missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 53.4% year on year to $620.4 million. Next quarter’s revenue guidance of $635 million... 
Via StockStory
2 Cash-Producing Stocks to Research Further and 1 to Question
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Topics Artificial Intelligence
Winners And Losers Of Q4: Evolent Health (NYSE:EVH) Vs The Rest Of The Healthcare Technology for Providers Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Evolent Health (NYSE:EVH) and... 
Via StockStory
2 of Wall Street’s Favorite Stocks Worth Investigating and 1 to Brush Off
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Unpacking Q4 Earnings: Omnicell (NASDAQ:OMCL) In The Context Of Other Healthcare Technology for Providers Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Omnicell (NASDAQ:OMCL) and the best and... 
Via StockStory
Q4 Earnings Highs And Lows: Premier (NASDAQ:PINC) Vs The Rest Of The Healthcare Technology for Providers Stocks
Looking back on healthcare technology for providers stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Premier (NASDAQ:PINC) and its peers. 
Via StockStory
Topics Economy
1 Profitable Stock with Solid Fundamentals and 2 to Steer Clear Of
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
Healthcare Technology Stocks Q4 In Review: Hims & Hers Health (NYSE:HIMS) Vs Peers
Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
Q4 Rundown: Astrana Health (NASDAQ:ASTH) Vs Other Healthcare Technology for Providers Stocks
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Astrana Health (NASDAQ:ASTH) and its peers. 
Via StockStory
Medicare Advantage Rates Expected To Climb Over 5% In 2026, Easing Pressure On Managed Care
CMS raises 2026 Medicare Advantage payments by 5.06%, exceeding projections and benefiting insurers focused on value-based care. 
Via Benzinga
Assessing Astrana Health: Insights From 6 Financial Analysts
Via Benzinga
2 Healthcare Stocks with Solid Fundamentals and 1 to Turn Down
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
2 Reasons to Like ASTH and 1 to Stay Skeptical
What a brutal six months it’s been for Astrana Health. The stock has dropped 47.7% and now trades at $29.91, rattling many shareholders. This may have investors wondering how to approach the... 
Via StockStory
Q4 Earnings Review: Healthcare Technology for Providers Stocks Led by Phreesia (NYSE:PHR)
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Phreesia (NYSE:PHR) and its peers. 
Via StockStory
1 Stock Under $50 with Solid Fundamentals and 2 to Turn Down
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Phreesia (PHR) To Report Earnings Tomorrow: Here Is What To Expect
Healthcare technology company Phreesia (NYSE:PHR) will be reporting results tomorrow after the bell. Here’s what to look for. 
Via StockStory
Why Astrana Health (ASTH) Shares Are Sliding Today
Shares of healthcare services company Astrana Health fell 31.9% in the afternoon session after the company reported weak fourth quarter results, its full-year EBITDA guidance missed significantly and... 
Via StockStory
Friday's session: top gainers and losers
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
These stocks are gapping in today's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
Astrana Health’s (NASDAQ:ASTH) Q4 Sales Beat Estimates
Healthcare services company Astrana Health announced better-than-expected revenue in Q4 CY2024, with sales up 88.4% year on year to $665.2 million. The company expects the full year’s revenue to be... 
Via StockStory
Topics Earnings
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.